VEGFA and nonpapillary renal cell carcinoma: Metastatic ccRCC are pharmacologically managed, targeted therapy utilizing tyrosine kinase inhibitors (TKIs), anti-VEGF antibodies, mammalian target of rapamycin (mTOR), and/or immune checkpoint inhibitors are widely used in first and second line treatments, suggesting that treatment strategy is crucial for ccRCC treatment (2).